SEGMENT REPORTING (Tables)

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Schedule of financial information by reportable segments

Financial information by reportable segment is as follows:

	Year Ended December 31, 2024
	Generics and Other		Rare Disease and Brands		Corporate and Unallocated		Total
Net Revenues	$	320,034	$	294,342	$	—	$	614,376
Cost of sales (excluding depreciation and amortization)	(168,371)		(81,839)		—		(250,210)
Research and Development	(30,519)		(14,062)		—		(44,581)
Selling, general, and administrative	(5,120)		(125,972)		(118,544)		(249,636)
Depreciation and amortization	—		—		(67,731)		(67,731)
Fair value adjustment	—		—		619		619
Gain on sale of building	—		—		5,347		5,347
Intangible asset impairment charge	—		—		(7,600)		(7,600)
Operating Income (Loss)	$	116,024	$	72,469	$	(187,909)	$	584
Unrealized gain on investment in equity securities	$	—	$	—	$	6,307	6,307
Interest expense, net	—		—		(17,602)		(17,602)
Other expense, net	—		—		(4,033)		(4,033)
Loss on extinguishment of debt	—		—		(7,468)		(7,468)
Income (Loss) Before Expense (Benefit) for Income Taxes	$	116,024	$	72,469	$	(210,705)	$	(22,212)

	Year Ended December 31, 2023
	Generics and Other		Rare Disease and Brands		Corporate and Unallocated		Total
Net Revenues	$	289,314	$	197,502	$	—	$	486,816
Cost of sales (excluding depreciation and amortization)	(152,739)		(28,774)		—		(181,513)
Research and Development	(28,197)		(6,089)		—		(34,286)
Selling, general, and administrative	(2,451)		(73,466)		(85,780)		(161,697)
Depreciation and amortization	—		—		(59,791)		(59,791)
Fair value adjustment	—		—		(1,426)		(1,426)
Restructuring activities	—		—		(1,132)		(1,132)
Operating Income (Loss)	$	105,927	$	89,173	$	(148,129)	$	46,971
Interest expense, net	—		—		(26,940)		(26,940)
Other expense, net	—		—		(159)		(159)
Income (Loss) Before Expense for Income Taxes	$	105,927	$	89,173	$	(175,228)	$	19,872

	Year Ended December 31, 2022
	Generics and Other		Rare Disease and Brands		Corporate and Unallocated		Total
Net Revenues	$	235,237	$	81,148	$	—	$	316,385
Cost of sales (excluding depreciation and amortization)	(125,835)		(12,950)		—		(138,785)
Research and Development	(19,964)		(2,354)		—		(22,318)
Selling, general, and administrative	(3,963)		(55,306)		(64,775)		(124,044)
Depreciation and amortization	—		—		(56,972)		(56,972)
Fair value adjustment	—		—		(3,758)		(3,758)
Restructuring activities	—		—		(5,679)		(5,679)
Intangible asset impairment charge	—		—		(112)		(112)
Operating Income (Loss)	$	85,475	$	10,538	$	(131,296)	$	(35,283)
Interest expense, net	—		—		(28,052)		(28,052)
Other income, net	—		—		670		670
Income (Loss) Before Benefit for Income Taxes	$	85,475	$	10,538	$	(158,678)	$	(62,665)

Schedule of revenue by geographic operations

The following table depicts the Company’s revenue by geographic operations during the following periods:

(in thousands)	Years Ended December 31,
Location of Operations	2024		2023		2022
United States	$	604,989	$	486,251	$	312,427
International	9,387		565		3,958
Total Revenue	$	614,376	$	486,816	$	316,385

Schedule of property, plant and equipment, net by geographic location

(in thousands)	December 31, 2024		December 31, 2023
United States	$	54,730	$	43,163
International	2,133		1,430
Total property and equipment, net	$	56,863	$	44,593